GLP-1 access in District of Columbia: telehealth rules, licence lookups and Medicaid coverage

The card above is District of Columbia's record from our state data file, and the sections below say what each line means and where it comes from. Rules on this page were checked on September 4, 2026; the linked sources are the authority if anything has moved since.

Who licenses prescribers in District of Columbia

Physicians who treat patients located in District of Columbia are licensed by the DC Board of Medicine (DC Health licence verification). The board's lookup is at dohenterprise.my.site.com/ver/s/, which loaded when we checked on September 4, 2026. Nurse practitioners are licensed by the state nursing board and physician assistants by the medical board or their own board, depending on the state; the prescriber licence explainer walks through each search and what an active record does and does not tell you. Cross-check the name against the federal NPI Registry, which lists every US prescriber with credential and practice location.

The pharmacy that fills the prescription is licensed by the DC Board of Pharmacy. That includes pharmacies in other states that ship to a District of Columbia address; they hold a non-resident licence from the same board. The Compounding Explained site covers what to search for once you are on the board site.

Telehealth prescribing in District of Columbia

District of Columbia allows a prescription for a non-controlled drug after a telehealth visit, with conditions. A DC-licensed physician may evaluate and prescribe for a new patient by telemedicine without a prior in-person visit, provided the evaluation is adequate to establish diagnoses and, absent prior face-to-face contact, is done through real-time audio or audio-video communication. The text we read is D.C. Board of Medicine Policy No. 15-01 (Telemedicine) ¶¶ 1.1, 1.6, 1.8; codified rule 17 DCMR § 4618 (eff. 12/22/2017), a board policy statement rather than a statute, on September 4, 2026. Read the condition carefully before assuming a questionnaire-only program meets it.

District of Columbia participates in the Interstate Medical Licensure Compact, the expedited licensing route for physicians who already hold a full licence in another member state. A compact licence is a full District of Columbia licence and shows up on the board lookup like any other. Issuing letters of qualification and licences; the Commission counts DC among its two participating territories. None of this covers controlled substances, which add a federal layer; GLP-1s are not controlled. The cross-state telehealth explainer has the general pattern.

Medicaid and anti-obesity drugs in District of Columbia

As of January 2026, District of Columbia Medicaid fee-for-service did not cover GLP-1s prescribed for obesity (Wegovy, Zepbound, Saxenda for weight management). Source: KFF: Medicaid Coverage of and Spending on GLP-1s, Figure 1 state map (published January 16, 2026). Coverage of the same molecules for type 2 diabetes (Ozempic, Mounjaro) is a separate question and is usual. Federal law lets states exclude "agents used for weight loss" from Medicaid drug coverage (42 U.S.C. 1396r-8(d)(2)), which is why coverage varies state by state and can change with a budget. Managed-care plans in District of Columbia may follow the state list or their own; the preferred drug list explainer shows where to look.

Compounded GLP-1s in District of Columbia

We have not found a District of Columbia-specific statute, rule or board notice on compounded GLP-1s that we could verify, so this page does not state one. The DC Board of Pharmacy is the regulator for a 503A pharmacy in the state and for non-resident pharmacies shipping into it; its newsletters and board minutes are where a state position would appear. The federal baseline applies everywhere: FDA declared the tirzepatide shortage resolved on December 19, 2024 and the semaglutide shortage resolved on February 21, 2025, and after the enforcement-discretion periods it announced (503A pharmacies through February 18, 2025 for tirzepatide and April 22, 2025 for semaglutide) pharmacies may not compound what is essentially a copy of an approved product outside the narrow exceptions in federal law (FDA statement). On March 3, 2026 FDA sent warning letters to 30 telehealth companies over the marketing of compounded GLP-1s (FDA press release). Compounded semaglutide and tirzepatide are not FDA approved and are not interchangeable with Wegovy, Zepbound, Ozempic or Mounjaro.

Before you buy from a telehealth offer in District of Columbia

1. Ask for the prescriber's full name and look it up on the DC Board of Medicine (DC Health licence verification) lookup above. An active licence in District of Columbia is the minimum, not an endorsement.
2. Ask which pharmacy will fill the prescription and check it on the DC Board of Pharmacy site, including a non-resident licence if the pharmacy is elsewhere.
3. If the product is compounded, expect it to be described as compounded and not FDA approved, and ask for the certificate of analysis. The Compounding Explained site has a vetting checklist; the FormBlends regulatory status page tracks the federal position.
4. Price the offer against brand self-pay programs and other compounded programs using the GLP-1 Pricing Index and the FormBlends cost report, and use the clinic fit quiz to decide which care model suits you. If you are new to tirzepatide, the FormBlends tirzepatide introduction covers the drug itself, and the FormBlends directory lists licensed providers and pharmacies.